On March 21, the Court of Appeals for the Federal Circuit held in a precedential opinion that legal fees incurred by generic drug companies in defending against patent infringement suits brought under the Hatch-Waxman Act...more
3/26/2025
/ Abbreviated New Drug Application (ANDA) ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Hatch-Waxman ,
Internal Revenue Code (IRC) ,
IRS ,
Litigation Fees & Costs ,
Patent Infringement ,
Patent Litigation ,
Pharmaceutical Industry ,
Precedential Opinion ,
Tax Deductions
On June 14, 2022, the U.S. Court of Appeals for the Third Circuit affirmed the dismissal of a securities suit brought by investors in pharmaceutical company, Amarin Corporation, PLC, holding that the investors had failed to...more
7/1/2022
/ Blockchain ,
Board of Directors ,
Class Action ,
Dismissals ,
False Statements ,
Food and Drug Administration (FDA) ,
Government Investigations ,
Misleading Statements ,
Putative Class Actions ,
Rule 10b-5 ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Litigation ,
Securities Violations ,
Shareholder Litigation ,
Subpoenas